Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy

Yohei Ozawa, Toru Nakano, Yusuke Taniyama, Tadashi Sakurai, Yu Onodera, Kurodo Kamiya, Makoto Hikage, Chiaki Sato, Kai Takaya, Takuro Konno, Michiaki Unno, Takashi Kamei

Research output: Contribution to journalArticlepeer-review

5 Citations (Scopus)

Abstract

Background: The impact of sarcopenia on digestive cancer is widely known. Muscle mass, defined as the psoas muscle index (PMI), is an important parameter of sarcopenia. However, the relationship between esophageal cancer and PMI has not been fully investigated, especially in patients receiving neoadjuvant therapy. Methods: To elucidate the influence of the PMI on patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy, the progression of sarcopenia defined by the PMI, the relationship between pretherapeutic/preoperative sarcopenia and patient characteristics, and patient survival were retrospectively investigated in 82 patients with esophageal squamous cell carcinoma who underwent neoadjuvant therapy. Results: The PMI decreased by more than 20 mm2/m2 between the pretherapeutic and preoperative periods in 75.6% of the patients. Pretherapeutic sarcopenia (low PMI) correlated with the pathological therapeutic response, postoperative recurrence, and pretherapeutic body mass index. Neoadjuvant chemoradiotherapy was associated with the progression of sarcopenia. The pretherapeutic sarcopenia group (low PMI) had worse disease-free survival (DFS) than the non-sarcopenia group. Furthermore, pretherapeutic sarcopenia (low PMI) was an independent prognostic risk factor of DFS according to univariate and multivariate analyses. Conclusions: The PMI may decrease during neoadjuvant therapy, especially during neoadjuvant chemoradiotherapy. Pretherapeutic sarcopenic (low PMI) patients should be followed-up more carefully postoperatively because higher risks of recurrence and poorer rates of disease-free survival are associated with these patients.

Original languageEnglish
Pages (from-to)345-351
Number of pages7
JournalEsophagus
Volume16
Issue number4
DOIs
Publication statusPublished - 2019 Oct 1

Keywords

  • Esophageal cancer
  • Neoadjuvant therapy
  • Psoas muscle index
  • Sarcopenia

ASJC Scopus subject areas

  • Gastroenterology

Fingerprint

Dive into the research topics of 'Evaluation of the impact of psoas muscle index, a parameter of sarcopenia, in patients with esophageal squamous cell carcinoma receiving neoadjuvant therapy'. Together they form a unique fingerprint.

Cite this